An article posted on CNN.Money.com illustrates the effect that dangerous staph infections and superbugs are having not only on our health, but also our economy. In response to the MRSA epidemic that is sweeping the nation, smaller biotechnology companies are taking the lead away from big pharmaceutical corporations in developing antibiotics that can combat this new generation of deadly "superbugs." Because bacteria have grown resistant to antibiotics, it is necessary to create new drugs that will be able to stop the epidemic. "Drug resistance is on the rise and old drugs are working less well," said Jason Kantor, analyst for RBC Capital Markets. "MRSA is the big driver currently." Lately, MRSA has gained attention by appearing in more public places, such as schools, and taking the lives of young children. Some of the most high-profile deaths occurred last year, when a 17-year-old high school student in Virginia and a 12-year-old student in New York both died from the drug-resistant strain. This year, two members of a high school wrestling team in Nebraska became infected with MRSA, increasing concerns about in-school infections and contact sports. While the most common superbug is MRSA, there are more types of superbugs that are evolving as threats to public health. To read more,
click here.